Liquid ventilation.
Partial liquid ventilation (PLV) developed considerably in the clinical and experimental fields during the past few years. In addition to improved oxygenation and lung mechanics by perfluorocarbon (PFC) administration, recent animal studies have tried to optimize PLV by evaluating the most appropriate ventilatory mode to use during PLV and by adjusting the best level of positive end-expiratory pressure (PEEP). Other pathophysiological aspects of acute lung injury that may be positively affected by liquid ventilation have been studied, including regional blood flow redistribution, reduction in ventilator-induced lung injury, and antiinflammatory properties of PFC. Although the precise dosing of PFC is debated, evidence from several experimental studies supports the use of smaller doses of PFC because larger doses increase the occurrence of baro- and volutrauma. In the clinical field, after promising data from preliminary studies, an international randomized controlled trial is on the verge of completion.
Ricard
J D
JD
Department of Critical Care, Louis Mourier Hospital, Colombes, and INSERM U82, Paris, France. ricard@bichat.inserm.fr
Lemaire
F
F
D005466:Fluorocarbons / Q000627:therapeutic use; D006801:Humans; D006931:Hyperbaric Oxygenation; D021061:Liquid Ventilation / Q000009:adverse effects / Q000379:methods*; D008168:Lung / Q000098:blood supply; D011175:Positive-Pressure Respiration / Q000379:methods; D012128:Respiratory Distress Syndrome / Q000503:physiopathology* / Q000628:therapy*
D005466:Fluorocarbons